|
Press Releases |
|
 |
|
Tuesday, October 14, 2025 |
|
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14 |
Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of its Tumor-Associated Antigen Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States. more info >> |
|
Thursday, October 9, 2025 |
|
Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology |
Everest Medicines today announced that the results of its Asian multicenter Phase III ENLIGHT UC study (ES101002) of etrasimod (VELSIPITY(R)) for the treatment of subjects with moderately to severely active ulcerative colitis (UC) have been published in the prestigious international journal The Lancet Gastroenterology & Hepatology, marking the global recognition of this next-generation selective S1P receptor modulator's efficacy in Asian patients. more info >> |
|
Monday, September 1, 2025 |
|
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D |
Everest Medicines (1952.HK) announced its interim results for the six months ended June 30, 2025. The Company's total revenue for the first half of 2025 reached RMB 446 million, representing 48% year-over-year growth, while operating expenses as a percentage of revenue decreased by 40.1 percentage points, reflecting strong operational efficiency. more info >> |
|
Friday, August 15, 2025 |
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC |
Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the 'Updated Guidelines'). Etrasimod, an S1P receptor modulator, is recommended for the induction of remission in patients with moderately to severely active UC and for continuation in the maintenance of remission, compared with no treatment after induction of remission. Both recommendations are strong, with a moderate quality of evidence. more info >> |
|
Thursday, August 14, 2025 |
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access |
Everest Medicines (HKEX 1952.HK, 'Everest') today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY' (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). more info >> |
|
Friday, August 8, 2025 |
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan |
Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON'. more info >> |
|
Tuesday, August 5, 2025 |
|
NEFECON(R) Receives NMPA Approval for Production Expansion in China, as Everest Medicines Accelerates Accessibility and Capacity Efforts |
Everest Medicines (HKEX 1952.HK) today announced that the supplemental application for the production expansion of NEFECON has been officially approved by China's National Medical Products Administration (NMPA). more info >> |
|
Saturday, August 2, 2025 |
|
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies |
Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash. more info >> |
|
Friday, July 25, 2025 |
|
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million |
Everest Medicines (HKEX 1952.HK, Everest or the " Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the "Sellers"), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue. more info >> |
|
Friday, July 4, 2025 |
|
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation |
Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company's progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
MHI Thermal Systems Air-Conditioners for the Australian Market Recognized with Prestigious Awards
Oct 17, 2025 23:37 JST
|
|
|
SEKISUI CHEMICAL, Fujitsu, and SAP Japan announce comprehensive modernization of management platform to drive data-driven approach
Oct 17, 2025 23:00 JST
|
|
|
Blockpass and RWA Inc. Partner to Effect Verifiable Trust in Real World Asset & DePIN Tokenization
Oct 17, 2025 17:00 HKT/SGT
|
|
|
TransNusa to Launch Bali - Singapore Scheduled Flight on November 17
Oct 17, 2025 16:58 JST
|
|
|
MHIEC Receives Contract for Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kanazawa
Oct 16, 2025 23:57 JST
|
|
|
Canada Backs Advanced Tokenization and Distributed Federated Learning Research with Over $3 Million in Funding
Oct 16, 2025 22:45 HKT/SGT
|
|
|
Overview of Honda Exhibits at Japan Mobility Show 2025
Oct 16, 2025 23:20 JST
|
|
|
DENSO to Exhibit at JAPAN MOBILITY SHOW 2025
Oct 16, 2025 22:53 JST
|
|
|
Fujitsu and IISc launch joint research on advanced AI technologies to accelerate new material development and resolve societal challenges
Oct 16, 2025 21:55 JST
|
|
|
Kincora Appoints Kerry Stevenson and Michelle Borromeo to the Advisory Board
Oct 16, 2025 20:09 HKT/SGT
|
|
|
45th Electronics Fair and electronicAsia attract some 60,000 buyers
Oct 16, 2025 19:06 HKT/SGT
|
|
|
Radisson Expands Ongoing Step-Out Drill Program at O'Brien to 140,000 Metres
Oct 16, 2025 18:39 HKT/SGT
|
|
|
How DPC Dash-Domino's Pizza China Is Capturing China's Pizza Market
Oct 16, 2025 14:30 HKT/SGT
|
|
|
SERES Passes HKEX Listing Hearing - First 'A+H' Dual-Listed Premium NEV Maker Poised for Hong Kong Debut
Oct 16, 2025 14:28 HKT/SGT
|
|
|
Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models
Oct 16, 2025 13:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|